---
title: Japan Early Diabetes Intervention Study
nct_id: NCT00464594
overall_status: UNKNOWN
phase: NA
sponsor: Japan Early Diabetes Intervention Study Group
study_type: INTERVENTIONAL
primary_condition: Diabetes Mellitus
countries: Japan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00464594.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00464594"
ct_last_update_post_date: 2007-04-24
last_seen_at: "2026-05-12T07:07:22.043Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Japan Early Diabetes Intervention Study

**Official Title:** A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention

**NCT ID:** [NCT00464594](https://clinicaltrials.gov/study/NCT00464594)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 2560
- **Lead Sponsor:** Japan Early Diabetes Intervention Study Group
- **Conditions:** Diabetes Mellitus
- **Start Date:** 2007-04
- **CT.gov Last Update:** 2007-04-24

## Brief Summary

The purpose of this study is to compare the suppressive effect of two kinds of interventions on the worsening/progression to definite diabetes: standard lifestyle guidance and standard lifestyle guidance combined with pharmacological intervention (monotherapy with one of acarbose, metformin, or gliclazide).

## Detailed Description

In newly-diagnosed early diabetes patients, a randomized comparative study will be conducted to compare the suppressive effect of the following two kinds of interventions on the worsening/progression to definite diabetes which has a harmful hyperglycemia i.e. an increased risk of microangiopathy: standard education for the improvement of lifestyle in accordance with the "Guidelines for the Treatment of Diabetes Mellitus in Japan" of the Japan Diabetes Society (JDS) and standard lifestyle guidance combined with pharmacological intervention using the lowest possible dose of commercially available oral hypoglycemic agents (one of acarbose, metformin, or gliclazide) in Japan.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 69 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Results of 75-g oral glucose tolerance test (75 g OGTT)will be used to confirm FPG \<= 125 mg/dL, 2-h PG \>= 200 mg/dL and HbA1c \<= 6.9%

Exclusion Criteria:

* Type 1 diabetes mellitus
* Undergoing treatment with steroids
* Secondary diabetes mellitus
* Diabetes mellitus due to suspected gene abnormalities
* BMI \>= 35 kg/m2 or BMI \< 18.5 kg/m2
* Undergone a surgery
* Severe hyperuricemia (gout) associated with organ dysfunction
* Severe vascular diseases with organ dysfunction
* Cancer or other malignant neoplasms
* Liver cirrhosis or chronic hepatic, chronic renal failure
* Gastrointestinal disorders
* Always performing rigorous muscular exercise
* Severe infection or serious trauma
* Women who are pregnant
* Alcohol dependence or drug dependence
* Drug allergy
* Anemic
* Abnormal hemoglobinuria
* Severe mental disease
```

## Interventions

- **Standard lifestyle guidance** (BEHAVIORAL)
- **Lifestyle guidance and monotherapy with acarbose** (DRUG)
- **Lifestyle guidance and monotherapy with metformin** (DRUG)
- **Lifestyle guidance and monotherapy with gliclazide** (DRUG)

## Primary Outcomes

- **FPG >= 140mg/dl and HbA1c >= 7.0%**

## Locations (1)

- Tokyo Medical and Dental University, Tokyo, Japan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tokyo medical and dental university|tokyo||japan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00464594.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00464594*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*